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In a matched case–control study using the General Practice Research Database, current statin use was not associated with a
significantly altered risk of any of 13 studied cancers. Untreated hyperlipidaemia was associated with slightly increased risks of colon
cancer (relative risk 1.8; 95% confidence interval 1.2–2.8), prostate cancer (1.5; 1.1–2.0), and bladder cancer (1.9; 1.2–3.1).
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Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase
(‘statins’) inhibit the rate-limiting step in cholesterol synthesis.
Rodent studies indicate that statins are carcinogenic (Newman and
Hulley, 1996). Other evidence, however, suggests that statins may
inhibit the growth of cancer cells by triggering apoptosis (Muller
et al, 1998; Dimitroulakos et al, 2002; Wong et al, 2002), inhibiting
angiogenesis (Weis et al, 2002; Park et al, 2002), or impairing the
metastatic process (Alonso et al, 1998; Kusama et al, 2002). We
undertook a matched case–control study of the relation between
statin use and cancer risk.
SUBJECTS AND METHODS
We carried out this study using information from the General
Practice Research Database (GPRD). General practitioners enter
patient data into computerised medical records and use the
software to generate prescriptions, providing a complete record of
medications (Jick et al, 1991; Jick et al, 2003). Cancer diagnoses are
highly reliable when validated against consultants’ letters and
hospital discharge summaries (Jick et al, 1997), and age-specific
time trends in the incidence of breast cancer, for example, are
closely similar to those reported by the Office for National
Statistics (Kaye et al, 2000).
Base population
The base population comprised all subjects 50–89 years old who
used antihyperlipidaemic drugs or had a recorded diagnosis of
untreated hyperlipidaemia. We also included a random sample of
50000 subjects of the same ages who neither used antihyperlipi-
daemic drugs nor had a recorded diagnosis of hyperlipidaemia.
We excluded subjects diagnosed with any cancer other than the
study cancer diagnoses (see below), and restricted our analysis to
subjects who had at least 3 years of follow-up time in the GPRD
(median 6.4, maximum 13.7).
Cases and controls
We identified all subjects who had a first-time recorded diagnosis
of any of 13 cancer diagnoses during 1990–2002. The study
cancers were melanoma (79 cases) and carcinomas of the
oesophagus (100), stomach (126), pancreas (125), colon (329),
rectum (183), lung (605), prostate (569), kidney (39), bladder
(227), breast (698), ovary (91), and endometrium (73). We
identified up to five controls for each case matching on year of
birth, sex, general practice, year of entry into the GPRD, and index
date.
Exposure
We analysed exposure to statins and nonstatins (fibrates,
cholestyramine, colestipol, nicotinic acid, and acipimox). Subjects
with a recorded diagnosis of hyperlipidaemia but no treatment
composed a separate exposure category. We considered subjects to
be current statin users if they received a prescription for a statin
within the year before their index date and their first prescription
was recorded more than a year before the index date. The median
and maximum durations of statin use among current users were 29
and 124 months. The reference exposure group comprised subjects
who had no history of hyperlipidaemia and no recorded use of
antihyperlipidaemic drugs.
Potential confounders
Body mass index was estimated based on each subject’s first
recorded weight within 1–5 years before the index date. Smoking
was categorised as current, past, none, or unknown. Analyses
were also adjusted for the average visit frequency during follow-up
in the GPRD before the index date (0–1, 2–5, or 6þ visits
per year).
Statistical methods
We used conditional logistic regression to estimate the relative risk
(odds ratio) for each of the study cancers in relation to exposure
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y(PHREG procedure, SAS, version 8.02, SAS Institute Inc., Cary, NC,
USA). We evaluated regression models including (1) only the main
exposure variables conditional on the matching factors; (2) also
smoking, body mass index, and average visit frequency; and (3) the
exposure variables and whichever potential confounders were
significantly associated with each cancer. We report results from
the model that provided the best fit to the data for each cancer by
likelihood ratio testing.
RESULTS
We identified 3244 cases and 14844 controls (Table 1). Men and
women were approximately equally represented. Current smoking
was more prevalent among cases than controls.
Current statin use
In all, 256 cases (7.9%) and 1066 controls (7.2%) were currently
exposed to statins. Among current statin users, the overall relative
risk for any study cancer was 1.0 (95% confidence interval 0.9–1.2)
compared to the reference exposure group. For no specific cancer
type was there a significantly altered relative risk among current
statin users (Table 2). We did, however, find marginally
significantly increased risks of 3.5 (1.1–10.9) and 4.2 (1.0–16.6)
for colon cancer and rectal cancer among current statin users of 60
months or longer (estimates based on five and four exposed cases,
respectively). However for both these cancers, the relative risks
among current statin users with 24–59 months exposure (0.9 [0.4–
1.8] and 1.4 [0.6–3.2]) were similar to those with less than 24
months duration (0.8 [0.4–1.9] and 1.2 [0.5–3.0], respectively).
Current use of other antihyperlipidaemic drugs
For no specific cancer was there a significantly altered relative risk
among current users of other antihyperlipidaemic drugs.
Past use of statins and/or other antihyperlipidaemic drugs
Among 169 past statin users with no exposure to other
antihyperlipidaemic drugs, 198 past users of other antihyperlipi-
daemic drugs with no exposure to statins, and 30 past users of both
statins and other antihyperlipidaemic drugs, we observed in-
creased relative risks for breast cancer (2.0; 1.2–3.1), endometrial
cancer (5.3; 1.4–20.6), and ovarian cancer (5.5; 1.5–21.2).
However, because the median duration of statin use among past
statin users was 2 months (interquartile range o1–12 months),
these results are not compatible with a biologically plausible
association between past statin use and cancer risk.
Untreated hyperlipidaemia
Among this group, we observed significantly increased risks of
colon cancer (1.8; 1.2–2.8), prostate cancer (1.5; 1.1–2.0), and
bladder cancer (1.9; 1.2–3.1).
DISCUSSION
This study provides evidence that statin use is not associated with
a substantially increased or decreased risk of the cancers we
studied. However, we found that untreated hyperlipidaemia was
associated with slightly increased risks of colon (1.8; 1.2–2.8),
prostate (1.5; 1.1–2.0), and bladder cancer (1.9; 1.2–3.1).
Although the results of one randomised study suggested an
increased risk of breast cancer associated with pravastatin use
(Sacks et al, 1996), subsequent meta-analyses of clinical trials
(Hebert et al, 1997; Bjerre and LeLorier, 2001; Pfeffer et al, 2002)
have indicated that statin use is not associated with any increase in
cancer risk.
In a nested case–control study using administrative databases
in Montreal, Blais et al (2000) found a decreased risk of cancer
(0.72; 0.57–0.92) among statin users compared with users of other
lipid lowering drugs. As the base population included only users of
lipid-lowering drugs, this study could not directly evaluate whether
statins users have a higher or lower risk of cancer than nonusers.
In another case–control study using data from interviews
conducted in hospitals in four US metropolitan areas, Coogan
et al (2002) found an increased risk of breast cancer (1.5; 1.0–2.3)
among statin users compared with nonusers, but this was largely
related to carcinoma in situ and may have been due to detection
bias. In a study based on the Saskatchewan population, Beck et al
(2003) found a slightly increased risk of breast cancer among older
statin users (1.15, 0.97–1.37), but the association was more evident
among short- than long-term users, arguing against a causal effect.
Table 1 Characteristics of cases and controls
Cases Controls
N % N %
Sex
Female 1585 48.9 7393 49.8
Male 1659 51.1 7451 50.2
Age (years)
50–59 460 14.2 2206 14.9
60–69 1066 32.9 5156 34.7
70–79 1201 37.0 5508 37.1
80–89 517 15.9 1974 13.3
Smoking
Smoker 668 20.6 2004 13.5
Ex-smoker 475 14.6 1809 12.2
Nonsmoker 1467 45.2 7763 52.3
Unknown 634 19.5 3268 22.0
BMI (kg/m
2)
o24 756 23.3 3026 20.4
24–28 851 26.2 4140 27.9
428 675 20.8 3048 20.5
Unknown 962 29.7 4630 31.2
Table 2 Relative risk of specific cancers in relation to current statin use
a
Cases Controls
N % N % RR 95% CI
Cancer
Oesophageal 9 9.0 34 7.9 0.8 0.3–1.8
Stomach 4 3.2 35 6.4 0.4 0.1–1.3
Colon 25 7.6 115 7.6 1.0 0.6–1.7
Rectal 23 12.6 59 7.0 1.6 0.9–2.8
Pancreatic 12 9.6 53 9.1 0.8 0.4–1.6
Lung 43 7.1 216 7.8 0.9 0.6–1.3
Melanoma 7 8.9 19 5.0 2.5 0.8–7.3
Breast 40 5.7 196 6.0 0.9 0.6–1.3
Endometrial 3 4.1 21 5.9 0.5 0.1–1.9
Ovarian 6 6.6 25 6.1 1.0 0.4–2.7
Prostate 62 10.9 204 8.2 1.3 1.0–1.9
Bladder 19 8.4 74 7.1 1.2 0.7–2.3
Kidney 3 7.7 15 8.0 1.0 0.3–4.2
aCurrent statin use is defined as at least one recorded prescription for a statin during
the year before the index date (with or without current use of other
antihyperlipidaemic drugs) with the first such prescription recorded at least 1 year
before the index date.
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hypothesis that statin use does not have a substantial effect on
cancer risk. Longer follow-up of subjects in the GPRD is needed to
determine whether these results remain consistent after more
prolonged periods of statin treatment.
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